Development and Validation of an RNA-Seq-Based Prognostic Signature in Neuroblastoma

被引:25
|
作者
Zhou, Jian-Guo [1 ,2 ]
Liang, Bo [3 ]
Jin, Su-Han [4 ]
Liao, Hui-Ling [5 ]
Du, Guo-Bo [6 ]
Cheng, Long [6 ]
Ma, Hu [1 ]
Gaipl, Udo S. [2 ]
机构
[1] Zunyi Med Univ, Affiliated Hosp, Dept Oncol, Zunyi, Guizhou, Peoples R China
[2] Univ Klinikum Erlangen, Dept Radiat Oncol, Erlangen, Germany
[3] Nanjing Univ Chinese Med, Affiliated Nanjing Hosp Chinese Med, Nanjing, Jiangsu, Peoples R China
[4] Zunyi Med Univ, Affiliated Stemmatol Hosp, Dept Orthodont, Zunyi, Guizhou, Peoples R China
[5] Southwest Med Univ, Coll Integrated Tradit Chinese & Western Med, Luzhou, Peoples R China
[6] North Sichuan Med Coll, Affiliated Hosp, Dept Oncol, Nanchong, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2019年 / 9卷
基金
中国国家自然科学基金;
关键词
neuroblastoma; gene pairs; prognostic model; validation; overall survival; event-free survival; PREDISPOSITION; IDENTIFICATION; PREDICTION;
D O I
10.3389/fonc.2019.01361
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: The stratification of neuroblastoma (NBL) prognosis remains difficult. RNA-based signatures might be able to predict prognosis, but independent cross-platform validation is still rare. Methods: RNA-Seq-based profiles from NBL patients were acquired and then analyzed. The RNA-Seq prognostic index (RPI) and the clinically adjusted RPI (RCPI) were successively established in the training cohort (TARGET-NBL) and then verified in the validation cohort (GSE62564). Survival prediction was assessed using a time-dependent receiver operating characteristic (ROC) curve and area under the ROC curve (AUC). Functional enrichment analysis of the genes was conducted using bioinformatics methods. Results: In the training cohort, 10 gene pairs were eventually integrated into the RPI. In both cohorts, the high-risk group had poor overall survival (OS) (P < 0.001 and P < 0.001, respectively) and favorable event-free survival (EFS) (P = 0.00032 and P = 0.06, respectively). ROC curve analysis also showed that the RPI predicted OS (60 month AUC values of 0.718 and 0.593, respectively) and EFS (60 month AUC values of 0.627 and 0.852, respectively) well in both the training and validation cohorts. Clinicopathological indicators associated with prognosis in the univariate and multivariate regression analyses were identified and added to the RPI to form the RCPI. The RCPI was also used to divide populations into different risk groups, and the high-risk group had poor OS (P < 0.001 and P < 0.001, respectively) and EFS (P < 0.05 and P < 0.05, respectively). Finally, the RCPI had higher accuracy than the RPI for the prediction of OS (60 month AUC values of 0.730 and 0.852, respectively) and EFS (60 month AUC values of 0.663 and 0.763, respectively) in both the training and validation cohorts. Moreover, these differentially expressed genes may be involved in certain NBL-related events. Conclusions: The RCPI could reliably categorize NBL patients based on different risks of death.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Development and validation of an RNA-seq based prognostic signature in neuroblastoma
    Zhou, J-G.
    Ma, H.
    ANNALS OF ONCOLOGY, 2019, 30
  • [2] DEVELOPMENT AND VALIDATION OF A RNA-SEQ BASED PROGNOSTIC SIGNATURE IN NEUROBLASTOMA
    Zhou, J.
    Ma, H.
    NEURO-ONCOLOGY, 2019, 21 : 5 - 5
  • [3] Development and validation of an RNA-seq-based transcriptomic risk score for asthma
    Cao, Xuan
    Ding, Lili
    Mersha, Tesfaye B.
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [4] Development and validation of an RNA-seq-based transcriptomic risk score for asthma
    Xuan Cao
    Lili Ding
    Tesfaye B. Mersha
    Scientific Reports, 12
  • [5] Identification of a RNA-seq-based signature to improve prognostics for uterine sarcoma
    Zhou, Jian-Guo
    Zhao, He-Tong
    Jin, Su-Han
    Tian, Xu
    Ma, Hu
    GYNECOLOGIC ONCOLOGY, 2019, 155 (03) : 499 - 507
  • [6] Development of a RNA-Seq Based Prognostic Signature in Lung Adenocarcinoma
    Shukla, Sudhanshu
    Evans, Joseph R.
    Malik, Rohit
    Feng, Felix Y.
    Dhanasekaran, Saravana M.
    Cao, Xuhong
    Chen, Guoan
    Beer, David G.
    Jiang, Hui
    Chinnaiyan, Arul M.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2017, 109 (01):
  • [7] Development and validation of a 21-gene prognostic signature in neuroblastoma
    Gupta, Mehul
    Kannappan, Sunand
    Jain, Mohit
    Douglass, David
    Shah, Ravi
    Bose, Pinaki
    Narendran, Aru
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [8] Development and validation of a 21-gene prognostic signature in neuroblastoma
    Mehul Gupta
    Sunand Kannappan
    Mohit Jain
    David Douglass
    Ravi Shah
    Pinaki Bose
    Aru Narendran
    Scientific Reports, 13
  • [9] An RNA-Seq-based reference transcriptome for Citrus
    Terol, Javier
    Tadeo, Francisco
    Ventimilla, Daniel
    Talon, Manuel
    PLANT BIOTECHNOLOGY JOURNAL, 2016, 14 (03) : 938 - 950
  • [10] Development and Validation of a Five-RNA-Based Signature and Identification of Candidate Drugs for Neuroblastoma
    Zhang, PeiPei
    Ma, KeXin
    Ke, XiaoFei
    Liu, Liu
    Li, Ying
    Liu, YaJuan
    Wang, YouJun
    FRONTIERS IN GENETICS, 2021, 12